)
John Gillespie
John Gillespie is President and CEO of AmberGen, having led the company since 2022, driving its strategic growth and commercial expansion. Under his leadership, AmberGen evolved from a grant-funded research company into a commercially oriented reagent innovator and now a drug-development partner through the creation of its MaxOmic™ CRO services platform, pioneering drug-inclusive, same-sample spatial hyper-multiomic imaging. This differentiated approach integrates spatial drug distribution with deep tissue molecular profiling to generate actionable mechanistic insight for development programs. Previously, John served in general management roles at Valeo SA, led worldwide R&D for three Johnson & Johnson businesses, held product development leadership roles at Baxter Healthcare, and helped found a startup medical device company. As a consultant, he advised 28 life science companies, including approximately 20 startups. He is a biomedical engineer with engineering degrees from Boston University, an MBA from Northwestern University’s Kellogg School of Management, and 24 patents.
-
28-Apr-2026Target Selection & Mechanisms of Action topic: Resolving tissue-level mechanism of action through drug-inclusive spatial multiomics
-
03-Nov-2026Poster Presentation: Seeing the Drug and Seeing What It Is Doing: Integrated Spatial PK/PD Analysis for Hybrid and Next-Generation Therapeutics
-
04-Nov-2026Poster Presentation: Where Does Your Therapy Go—and Where Does It Make a Difference? Connecting Tissue Biodistribution to Biological Response in Gene Therapy Development